<VariationArchive VariationID="1934149" VariationName="NM_000520.6(HEXA):c.1088dup (p.Ser364fs)" VariationType="Duplication" Accession="VCV001934149" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-03-05" DateCreated="2023-02-07" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1989153" VariationID="1934149">
      <GeneList>
        <Gene Symbol="HEXA" FullName="hexosaminidase subunit alpha" GeneID="3073" HGNC_ID="HGNC:4878" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="72340924" stop="72376014" display_start="72340924" display_stop="72376014" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="72635777" stop="72668519" display_start="72635777" display_stop="72668519" Strand="-" />
          </Location>
          <OMIM>606869</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000520.6(HEXA):c.1088dup (p.Ser364fs)</Name>
      <CanonicalSPDI>NC_000015.10:72347743:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="72347743" stop="72347744" display_start="72347743" display_stop="72347744" variantLength="1" positionVCF="72347743" referenceAlleleVCF="G" alternateAlleleVCF="GA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="72640084" stop="72640085" display_start="72640084" display_stop="72640085" variantLength="1" positionVCF="72640084" referenceAlleleVCF="G" alternateAlleleVCF="GA" />
      </Location>
      <ProteinChange>S364fs</ProteinChange>
      <ProteinChange>S375fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009017.3" sequenceAccession="NG_009017" sequenceVersion="3" change="g.33270dup">
            <Expression>NG_009017.3:g.33270dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000520.6" sequenceAccession="NM_000520" sequenceVersion="6" change="c.1088dup" MANESelect="true">
            <Expression>NM_000520.6:c.1088dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000511.2" sequenceAccession="NP_000511" sequenceVersion="2" change="p.Ser364fs">
            <Expression>NP_000511.2:p.Ser364fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001318825.2" sequenceAccession="NM_001318825" sequenceVersion="2" change="c.1121dup">
            <Expression>NM_001318825.2:c.1121dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001305754.1" sequenceAccession="NP_001305754" sequenceVersion="1" change="p.Ser375fs">
            <Expression>NP_001305754.1:p.Ser375fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.72347744dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.72347744dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.72640085dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.72640085dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009017.2" sequenceAccession="NG_009017" sequenceVersion="2" change="g.33436dup">
            <Expression>NG_009017.2:g.33436dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000520.6(HEXA):c.1088dup (p.Ser364fs) AND Tay-Sachs disease" Accession="RCV002631722" Version="2">
        <ClassifiedConditionList TraitSetID="1067">
          <ClassifiedCondition DB="MedGen" ID="C0039373">Tay-Sachs disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-08" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-07" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1833974</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8490625</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1067" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6027" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase A Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM2 gangliosidosis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HexA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase alpha-subunit deficiency (variant B)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis, Tay-Sachs</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Tay-Sachs disease</ElementValue>
                <XRef ID="Tay+Sachs+disease/7008" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010100" DB="MONDO" />
                <XRef ID="111385000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TSD</ElementValue>
                <XRef Type="MIM" ID="272800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity. This, in turn, depends on the molecular characteristics and biological impact of the HEXA pathogenic variants. HEX A is necessary for degradation of GM2 ganglioside; without well-functioning enzymes, GM2 ganglioside builds up in the lysosomes of brain and nerve cells. The classic clinical phenotype is known as Tay-Sachs disease (TSD), characterized by progressive weakness, loss of motor skills beginning between ages three and six months, decreased visual attentiveness, and increased or exaggerated startle response with a cherry-red spot observable on the retina followed by developmental plateau and loss of skills after eight to ten months. Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years. Subacute juvenile TSD is associated with normal developmental milestones until age two years, when the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline. Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration. Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis. Clinical variability even among affected members of the same family is observed in both the subacute juvenile and the late-onset TSD phenotypes.</Attribute>
                <XRef ID="NBK1218" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7737" />
                <XRef ID="7737" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301397</ID>
                <ID Source="BookShelf">NBK1218</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <XRef ID="845" DB="Orphanet" />
              <XRef ID="C0039373" DB="MedGen" />
              <XRef ID="MONDO:0010100" DB="MONDO" />
              <XRef Type="MIM" ID="272800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5659138" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="13253539|MedGen:C0039373" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002969226" DateUpdated="2024-02-28" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1833974</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8490625</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser364Leufs*15) in the HEXA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HEXA are known to be pathogenic (PMID: 1833974, 8490625). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with HEXA-related conditions. ClinVar contains an entry for this variant (Variation ID: 1934149). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HEXA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.72640084_72640085insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0039373" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5659138" TraitType="Disease" MappingType="XRef" MappingValue="C0039373" MappingRef="MedGen">
        <MedGen CUI="C0039373" Name="Tay-Sachs disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

